Project FDA spurs industry efficiency

Share this article:
Andrew von Eschenbach
Andrew von Eschenbach

Former FDA commissioner Andrew von Eschenbach has joined the Manhattan Institute to head up its Project FDA initiative, which aims to reduce development times for promising medical products by allowing them on the market faster under very close post-market surveillance. The initiative will look to Congress for support as it considers reform proposals as part of this year's user-fee reauthorization.

“Project FDA promotes reforms that can enable the FDA to offer a more predictable, transparent, and efficient pathway for bringing safe and effective new products to patients,” the group says.

According to the Biotechnology Industry Organization, the changes being discussed will seek to modernize the program and offer product developers the ability to use biomarkers and other measurements of a drug's effectiveness that weren't considered when the program was originated.

Under von Eschenbach's leadership, Project FDA says it will educate the public on FDA's “vital” role in advancing medical innovation; highlight the potential for new sciences to improve health and lower costs; and collaborate with patient and industry stakeholders to modernize the agency's policies and procedures.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Is your marketing strategy stuck in 2005?

Is your marketing strategy stuck in 2005?

It is not enough to just have a killer black book or Rolodex. The market needs agile, swift marketing

Is guidance stifling social media?

Recent FDA draft guidance was meant to help companies create FDA-compliant tweets and handle third-party misinformation on the web. What other obstacles lie in the path of effective social media use?

FDA social media guides draw flak

FDA social media guides draw flak

Two FDA guidance documents on how health product manufacturers may participate in social media have drawn criticism from industry and consumer groups.